IMMUNOME INC (IMNM)
US45257U1088 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to IMNM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 30.6. This target is 178.94% above the current price.
IMNM was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about IMNM.
In the previous month the buy percentage consensus was at a similar level.
IMNM was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-04-30 | JP Morgan | Initiate | Overweight |
| 2024-04-15 | Guggenheim | Initiate | Buy |
| 2024-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-19 | Wedbush | Initiate | Outperform |
| 2023-03-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-03-17 | Chardan Capital | Maintains | Buy |
| 2021-10-29 | Cantor Fitzgerald | Initiate | Overweight |